Similar articles

• [Prophylaxis and treatment of infections in immunosuppressed onco-hematologic patients].

  Carvalho Fde O, Sabbaga J. Carvalho Fde O, et al. Rev Hosp Clin Fac Med Sao Paulo. 1985 May-Jun;40(3):141-8. Rev Hosp Clin Fac Med Sao Paulo. 1985. PMID: 4095441 Portuguese. No abstract available.
• Management of infections in immunocompromised cancer patients.

  Bajetta E, Gasparini G, Monfardini S, Volonterio A, Buzzoni R, Shinde S. Bajetta E, et al. Haematologica. 1984 Sep-Oct;69(5):576-97. Haematologica. 1984. PMID: 6437936 Review. No abstract available.
• The results of a randomized trial of empirical antibiotic treatment in febrile neutropenic patients with four beta-lactam/aminoglycoside combinations.

  Hann I, Noone P, Prentice HG, Sage R, Blacklock H, Stirling L, Gray R, Corringham R, Boesen E, Mohiuddin J, et al. Hann I, et al. J Antimicrob Chemother. 1983 May;11 Suppl C:57-63. doi: 10.1093/jac/11.suppl_c.57. J Antimicrob Chemother. 1983. PMID: 6352605 Clinical Trial. No abstract available.
• Nosocomial infections due to gram-negative bacilli in compromised hosts: considerations for prevention and therapy.

  Klastersky J. Klastersky J. Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S552-8. Rev Infect Dis. 1985. PMID: 3909312 Review.
• Prospective randomly controlled trial of three antibiotic combinations for empirical therapy of suspected sepsis in neutropenic cancer patients.

  Gaya H, Klastersky J, Schimpff SC, Fière D, Widmaier S, Nagel G. Gaya H, et al. Eur J Cancer (1965). 1975 Aug;11suppl:5-8. doi: 10.1016/b978-0-08-019964-1.50005-1. Eur J Cancer (1965). 1975. PMID: 767119 Clinical Trial. No abstract available.